Chimera Research Group

previous arrow
next arrow

November 23 Biotech Update

The market dynamics remain the same.  We are entering what tends to be a seasonally positive period of the year, which might add some tailwind to the broader market.  While I still think the market is going to focus on the prospects of the vaccine coming next year as opposed to the out of control […]

November 20th Biotech Update

I think choppy might have been the best description of the market at this point.  This makes sense give the competing influences on both the market and economy.  I would not be surprised to see this chop continue or perhaps even see some consolidation.  The broader market seems in a little more precarious position than […]

November 19th Biotech Update

Nothing crazy happening in the market at this point.  I do not see anything that compelling low or high and I think the market continues to struggle with the hope of the vaccines versus the pain of an out of control spread.  There is likely a point where the immediate term gets so bad that […]

Mailing List



Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press


Log In

JoinLost Password?